Russian Registry of Patients With nAMD

Novartis

Status: Terminated

Conditions: Neovascular Age-Related Macular Degeneration

Treatments: Other: nAMD

Study type: Observational

Funder types: Industry

Identifiers

NCT04935411

CRTH258ARU01

Details and patient eligibility

About

A three-year, non-randomized, observational, multicenter prospective nAMD study - patient registry.

Full description

The registry is a structured system which uses observational study methods for systematic collection of data on health condition in the specific patient population.

Real world clinical practice data will be collected. Patients will not undergo any additional examinations or procedures that are outside of the standard clinical practice

Enrollment: 2,665 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > to 18 years
• Male or female patients diagnosed with nAMD (with or without previous treatment for nAMD including but not limited to PDT, laser coagulation, vitamins, retinolamine, emoxipine, anti-VEGF therapy or any surgery for nAMD).
• Willing and able to provide informed written consent personally or by legal proxy

Exclusion criteria

• The patient does not meet the inclusion criteria;
• The patient is simultaneously participating in a different nAMD therapy study.

Trial design

2,665 participants in 1 patient group

nAMD patients

Description:

patients diagnosed with Neovascular Age-Related Macular Degeneration

Treatment:

Other: nAMD